866-997-4948(US-Canada Toll Free)

20s Proteasome - Pipeline Review, H2 2018

Published By :

Global Markets Direct

Published Date : Oct 2018

Category :

Pharmaceutical

No. of Pages : 64 Pages

20s Proteasome - Pipeline Review, H2 2018

Summary

20s Proteasome pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report 20s Proteasome - Pipeline Review, H2 2018, outlays comprehensive information on the 20s Proteasome targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

20s Proteasome - 20S proteasome is the catalytic core of the 26S proteasome, the central protease of the ubiquitin pathway of protein degradation. It is commonly associated with regulatory complexes, which include the 19S Proteasome, the PA28 alpha/beta complex, or the PA28 gamma complex. The 20S Proteasome is composed of 28 subunits arranged into four stacked rings. Unlike the 26S proteasome, which degrades proteins in an ATP-dependent manner, the 20S proteasome is ATP-independent and only degrades entirely unfolded polypeptides.

The molecules developed by companies in Phase III, Phase II and Phase I stages are 2, 1 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease and Metabolic Disorders which include indications Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Multiple Myeloma (Kahler Disease), Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Amyloidosis, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Gliosarcoma, Graft Versus Host Disease (GVHD), Kidney Transplant Rejection, Lung Transplant Rejection, Malignant Glioma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Neuroendocrine Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Peripheral T-Cell Lymphomas (PTCL), Renal Cell Carcinoma, Small-Cell Lung Cancer, T-Cell Lymphomas and Tuberculosis.

Furthermore, this report also reviews key players involved in 20s Proteasome targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for 20s Proteasome
- The report reviews 20s Proteasome targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 20s Proteasome targeted therapeutics and enlists all their major and minor projects
- The report assesses 20s Proteasome targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 20s Proteasome targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 20s Proteasome
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 20s Proteasome development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
20s Proteasome - Overview
20s Proteasome - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
20s Proteasome - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
20s Proteasome - Companies Involved in Therapeutics Development
Amgen Inc
Celgene Corp
Centrax International Inc
20s Proteasome - Drug Profiles
carfilzomib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CX-13608 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
marizomib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oprozomib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit 20S Proteasome for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit 20s Proteasome for Tuberculosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
20s Proteasome - Dormant Products
20s Proteasome - Product Development Milestones
Featured News & Press Releases
Oct 01, 2018: FDA approves KYPROLIS (carfilzomib) once-weekly 70 mg/m2 in combination With Dexamethasone (Kd70) for patients with Relapsed Or Refractory Multiple Myeloma
Aug 27, 2018: Amgen Submits Supplemental New Drug Application For KYPROLIS (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone
Jun 11, 2018: FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS (carfilzomib) Label
Jun 01, 2018: Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma
May 09, 2018: UAB recruiting for clinical trial to determine therapies for eradication of multiple myeloma
Apr 30, 2018: Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS (carfilzomib) Label
Jan 30, 2018: Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To KYPROLIS (carfilzomib) Label
Jan 17, 2018: FDA Approves Addition Of Overall Survival Data To KYPROLIS (carfilzomib) Label
Jan 17, 2018: Overall Survival Analysis From KYPROLIS (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology
Dec 28, 2017: Carfilzomib can lead to cardiovascular toxicity in multiple myeloma patients
Dec 11, 2017: KYPROLIS (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial
Oct 23, 2017: Phase 3 A.R.R.O.W. Study Of Once-Weekly KYPROLIS (Carfilzomib) Regimen Meets Primary Endpoint Of Progression-Free Survival In Relapsed And Refractory Multiple Myeloma Patients
Aug 30, 2017: FDA Accepts Amgen's Filing Of A Supplemental New Drug Application To Add Overall Survival Results To KYPROLIS (Carfilzomib) Label
Aug 30, 2017: Long-Term Analysis Of Phase 3 Head-To-Head Study Confirms KYPROLIS (Carfilzomib) Regimen Extends Overall Survival In Patients With Relapsed Multiple Myeloma
Aug 23, 2017: Overall Survival Analysis From KYPROLIS Phase 3 Endeavor Trial Published In The Lancet Oncology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Amgen Inc, H2 2018
Pipeline by Celgene Corp, H2 2018
Pipeline by Centrax International Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *